NCT05489718已完成1 期
A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI324 in Subjects With Diabetic Macular Edema(DME)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Safety evaluation indicators
研究概览
简要总结
This study is designed as a Multi-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single and multiple intravitreal injections of IBI324 in subjects with DME
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to sign informed consent form and comply with visit and study procedures per protocol.
- •Male or female subjects with age of 18~80 yrs.
- •Diagnosis of diabetes mellitus(type 1 or 2), and current regular use of insulin or other injectable drugs or oral anti-hyperglycaemic agent for the treatment of diabetes.
- •Visual impairment was caused by DME involving the macular fovea.
- •Central macular sub-field thickness (CST) ≥320μm according to OCT.
- •BCVA score of 24-73 letters using ETDRS charts (in 4 meters) in the study eye.
- •Female subjects of childbearing age or male subjects with childbearing age female partner agree to take effective contraceptive measures from the screening period to 3 months after the end of treatment.
排除标准
- •Concomitant diseases that may cause subjects fail to respond to the treatment or confuse the interpretation of the study results.
- •PDR in the study eye.
- •Tractional retinal detachment, pre-retinal fibrosis, vitreomacular traction, or epiretinal membrane involving the fovea or disrupting the macular architecture in the study eye.
- •Active rubeosis in the study eye.
- •The equivalent spherical lens≤-8.00D in the study eye.
- •The intraocular pressure>21 mmHg in the study eye.
- •Active ocular or periocular inflammation/infection in either eye.
- •Prior any treatment of following in the study eye:
- •Intravitreal anti-VEGF treatment within 3 months prior to baseline;
- •Intraocular glucocorticoid injection within 3 months prior to baseline;
- •PRP, local/grid laser photocoagulation within 3 months prior to baseline;
- •Any intraocular surgery (e.g. cataract surgery) within 90 days prior to baseline;
- •The eyes were treated with lasik posterior capsulotomy or glaucoma filtration, radiotherapy 30 days before baseline;
- •Currently untreated diabetes mellitus or previously untreated DM subjects who initiated oral or injectable antidiabetic medication or insulin <90 days;
- •HbA1c of >10% within 28 days prior to baseline;
- •Presence of any systemic disease: including but not limited to unstable angina; cerebrovascular accident or transient cerebral ischemia (within 6 months prior to selection); myocardial infarction (within 6 months prior to selection); serious arrhythmia requiring medical treatment; liver, kidney or metabolic diseases; or malignant tumor;
- •History of severe hypersensitivity/allergy to active ingredients or any excipients of the study drug, or fluorescein and povidone iodine;
- •Pregnant or lactating women or women preparing to become pregnant or breastfeeding during the study period;
- •Participated in any clinical study of any other drug within three months prior to enrollment, or attempted to participate in other drug trials during the study;
- •Other conditions unsuitable for enrollment judged by investigators
结局指标
主要结局
Safety evaluation indicators
时间窗: Through study completion, a maximum of 24 weeks
Incidence, relatedness and severity of all adverse events, treatment emergent adverse events and serious adverse events b) Changes in central subfield thickness by OCT compared with baseline
次要结局
- Changes in visual acuity as measured by BCVA compared with baseline(Through study completion, a maximum of 24 week)
- Changes in the average thickness of the macula in the central 1 mm ETDRS grid (CST) compared with baseline(Through study completion, a maximum of 24 week)
- Pharmacokinetic (PK) profiles, such as half-life time (t1/2)，etc(Through study completion, a maximum of 24 weeks)
- The incidence of adverse events(Through study completion, a maximum of 24 weeks)
- Immunogenicity evaluation indicators(Through study completion, a maximum of 24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Study of IBI333 in Subjects With Neovascular Age-related Macular DegenerationNeovascular Age-related Macular DegenerationNCT05639530Innovent Biologics (Suzhou) Co. Ltd.17
已完成
1 期
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD PatientsNeovascular Age-related Macular DegenerationNCT04370379Innovent Biologics (Suzhou) Co. Ltd.18
已完成
1 期
A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular DegenerationNeovascular Age-related Macular DegenerationNCT03814291Innovent Biologics (Suzhou) Co. Ltd.31
Unknown
1 期
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaLymphomaMultiple MyelomaNCT04818372Keymed Biosciences Co.Ltd87
撤回
1 期
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.Non-small Cell Lung Cancer (NSCLC)EndometrialSolid TumorsOvarian CancerLiposarcomaBreast CancerNCT05905341Pfizer